CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & DrugsHouse : Cipla
BSE1494.6528.45 (+1.94 %)
PREV CLOSE ( ) 1466.20
OPEN PRICE ( ) 1469.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 60392
TODAY'S LOW / HIGH ( )1462.40 1513.10
52 WK LOW / HIGH ( )885.35 1519
NSE1496.9533.6 (+2.3 %)
PREV CLOSE( ) 1463.35
OPEN PRICE ( ) 1472.00
BID PRICE (QTY) 1496.95 (16)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2110407
TODAY'S LOW / HIGH( ) 1461.15 1514.20
52 WK LOW / HIGH ( )885.35 1519
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 17-08 1935
Management Info
Y K Hamied - Chairman Umang Vohra - Managing Director
Registered Office

Address Cipla House, Peninsula Business Park,Ganpatrao Kadam Marg,Lower Parel,
Mumbai,
Maharashtra-400013

Phone 022-24826000

Email contactus@cipla.com

Website www.cipla.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg, MCX
NEWS
27Mar Cipla partners with Sanofi India
Cipla has entered into exclusive partnership with Sanofi India (SIL) and..
27Mar Cipla surges on partnering with Sanofi
Cipla is currently trading at Rs. 1477.20, up by 5.50 points or 0.37% fr..
07Mar Cipla’s arm completes sale of entire s
Cipla’s wholly owned subsidiary -- Goldencross Pharma (Goldencross) has..
05Mar Update On Transfer Of Generics Busine
Update on transfer of Generics Business Undertaking of the Company to Ci..
02Mar Cipla transfers Generics Business Unde
Cipla has completed the transfer of Generics Business Undertaking as a g..
Financials
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit11141.425134.7
Gross Profit 13807.6 34405.4
Operating Profit 15248.442493.7
Net Sales 43813.3157906
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Abbott India (BSE)
 26946.00 (0.74%)
M.Cap (Rs. in Cr)57258.37
Sanofi India (BSE)
 8118.25 (2.06%)
M.Cap (Rs. in Cr)18696.83
Dr. Reddy's Lab (BSE)
 6155.15 (1.78%)
M.Cap (Rs. in Cr)102679.14
Divi's Lab (BSE)
 3436.75 (2.14%)
M.Cap (Rs. in Cr)91234.91
Glaxosmithkline Phar (BSE)
 1943.10 (3.26%)
M.Cap (Rs. in Cr)32917.29
Shareholding Pattern
PROMOTERS 33.47%
MUTUAL FUNDS/UTI 16.66%
NON-INSTITUTION 16.53%
FI/BANKS/INSURANCE 5.47%
GOVERNMENT 0%
FII 0%
ATTENTION INVESTORSKYCIPO
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.